KPV peptide: what it is, what it does and what the research shows

KPV is a tripeptide made of lysine, proline and valine. It is the last three amino acids of alpha-melanocyte-stimulating hormone (α-MSH), a 13-amino-acid hormone involved in skin pigmentation and inflammation, whose full sequence is SYSMEHFRWGKPV ^[1]. Researchers became interested in KPV because it appeared to keep much of α-MSH’s anti-inflammatory activity without the pigment-stimulating effect ^{[3] [12]}.

KPV is sometimes confused with melanotan II and PT-141, which are also derived from α-MSH. Those are larger synthetic peptides designed to act on melanocortin receptors. Whether KPV acts on those receptors at all is disputed, as explained below.

A 2008 review in Endocrine Reviews explained the background. α-MSH has broad anti-inflammatory effects in animal models of skin, gut, eye, airway and joint inflammation, but its effect on pigmentation has been one obstacle to using it as a drug. KPV was put forward as an alternative because it kept anti-inflammatory activity without the pigmentary action, and a related tripeptide, KdPT, was being studied for the same reason ^[12]. KPV is sold online as a research peptide; see what research peptides are for what that label does and does not mean.

In a 2003 mouse study of crystal-induced peritonitis, KPV reduced the build-up of white blood cells, but unlike α-MSH it did not raise cAMP in macrophages, and its effect was not blocked by a melanocortin receptor antagonist. The authors concluded KPV probably works through inhibition of interleukin-1β rather than through melanocortin receptors ^[2].

Gut research points to a transporter called PepT1, which carries small peptides into cells and is increased in the inflamed colon. In a 2008 study, nanomolar concentrations of KPV reduced activation of the inflammatory NF-κB and MAP kinase pathways in human intestinal cells and T cells, and its uptake depended on PepT1 ^[4]. Earlier laboratory work also reported that α-MSH and KPV inhibited Staphylococcus aureus and Candida albicans in culture ^[1].

Whether KPV binds melanocortin receptors is disputed. A 2010 review from the Münster group described KPV as lacking the entire sequence motif required for binding to any known melanocortin receptor ^[3]. An earlier 2003 paper from the same group, however, reported that KPV was able to bind the melanocortin-1 receptor (MC-1R) and modulate antigen-presenting cells ^[10], and a 2004 study found that KPV raised calcium signalling in hamster cells engineered to express MC-1R ^[11]. Against that, KPV still worked in mice lacking a functional MC-1R ^[5], and its effect in peritonitis was not blocked by a melanocortin antagonist ^[2]. The most consistent reading is that KPV’s anti-inflammatory action does not depend on melanocortin receptors, whether or not it can bind them.

Work in airway cells adds another route. In human bronchial epithelial cells, KPV reduced NF-κB signalling and the release of the inflammatory chemokines IL-8 and eotaxin; the study linked this to KPV entering the nucleus and interfering with how the NF-κB subunit p65 is imported into it ^[13]. In human skin cells, KPV did not raise cAMP but did trigger calcium signals under some experimental conditions ^[11]. These studies suggest KPV acts inside cells on inflammatory switches, but none of them measured effects in a person.

All published efficacy evidence for KPV comes from cell and animal studies. Searches for KPV peptide benefits usually concern gut inflammation, skin, wound healing and general inflammation. In short, what KPV peptide is good for in the literature is damping inflammation in cells and rodents, most convincingly in mouse colitis. The sections below take each in turn and say which species and which formulation each result came from, because most were produced with laboratory formulations that differ from the powders and capsules sold online.

In mouse colitis induced by the chemicals DSS or TNBS, KPV given in drinking water reduced inflammation and inflammatory cytokine levels ^[4]. A separate 2008 study found that KPV sped recovery and reduced inflammatory infiltrates in DSS colitis and in a T-cell transfer colitis model in mice, and rescued all treated mice lacking a functional melanocortin-1 receptor from death during DSS colitis ^[5].

Later work has focused on delivery. In a 2017 study, KPV loaded into hyaluronic-acid-coated nanoparticles and given by mouth in a hydrogel reduced mucosal damage and TNF-α in a mouse model of ulcerative colitis ^[6]. These are formulation experiments in mice and do not show effects in people.

Rat work has taken a similar path. In a 2022 study, KPV held in an adhesive hydrogel and given rectally to rats with TNBS colitis improved the healing of the colon lining more than KPV alone, and the treated rats had more of some gut bacteria regarded as beneficial ^[20]. The hydrogel was the point of the study, so the result says more about the delivery system than about KPV taken by mouth.

Delivery has been a recurring problem. In a 2010 mouse study from the group that described KPV’s PepT1 uptake, KPV packed into nanoparticles inside an alginate-chitosan gel protected mice from DSS colitis at a concentration 12,000 times lower than KPV in free solution ^[33]. A 2021 rat study noted that KPV solution is very unstable when given rectally and used a hydrogel to stabilise it before treating TNBS colitis ^[34]. A 2026 study attached KPV to a carrier designed to release it only where inflammation produces reactive oxygen species. In mice with colitis, the carrier form built up in the colon at 3.8 times the level of free KPV and worked at a 20-fold lower dose; given by mouth, it also reached inflamed lungs in mice with acute lung injury ^[27]. A 2024 study combined KPV with the immunosuppressant tacrolimus (FK506) in nanoparticles and found the combination restored gut barrier proteins better than either drug alone in acute and chronic mouse colitis ^[28].

A 2023 review of the melanocortin system in inflammatory bowel disease summarised a body of mouse colitis work and concluded that molecules acting on this system could become new treatments, which is the research context KPV sits in ^[29]. None of this has reached a human trial.

One mouse study looked at colitis-associated bowel cancer. Mice with more PepT1 in the gut developed more tumours after a chemical colitis-and-cancer protocol, and mice without PepT1 developed fewer. KPV prevented tumour formation in normal mice but had no effect in mice lacking PepT1, which fits the idea that KPV needs this transporter to act ^[14]. This is a single mouse study and has not been tested in people.

In a mouse model of allergic contact dermatitis, KPV applied to the skin or given systemically reduced both the sensitisation and the reaction phases of the allergy and induced tolerance to the allergen ^[10]. In 2025, a Korean group found that KPV protected human skin cells (HaCaT keratinocytes) from damage caused by fine airborne dust, reducing oxidative stress, cell death and the inflammatory signal IL-1β, including in a three-dimensional skin model ^[15].

A 2019 review argued that α-MSH fragments such as KPV are promising candidates for treating wounds and skin ulcers, while noting that the case rests on laboratory and animal models and setting out arguments for and against ^[16]. In the eye, a 2006 rabbit study found that KPV drops at 1, 5 or 10 mg/mL sped healing after the corneal surface was scraped away; 60 hours later all eight treated corneas had fully re-covered, and the effect was blocked by a nitric oxide synthase inhibitor ^[17].

In the mouth, a 2021 rat study used KPV in a temperature-sensitive gel that sticks to the gums to treat chemotherapy-induced mouth ulcers. Treated rats ate more, regained weight and had better-healed gum tissue. The gel also contained EGCG, an antibacterial green-tea compound, and was active against Staphylococcus aureus, including a resistant strain ^[18].

KPV has also been built into wound dressings. In a 2022 study, a three-layer film released KPV over about three days and then epidermal growth factor, and the combination significantly improved healing of full-thickness wounds in diabetic mice ^[30]. Because the film delivered two active ingredients, the result cannot be credited to KPV alone.

KPV for inflammation outside the gut has been studied in airway cells, where it reduced inflammatory signalling triggered by TNF-α and respiratory syncytial virus ^[13]. We found no animal or human study of KPV itself for arthritis, autoimmune disease or post-viral inflammation, conditions for which it is sometimes promoted.

Two 2026 papers from one Korean laboratory looked at fat. In mouse fat-precursor cells, KPV at 100 µg/mL cut fat build-up by about 55% on staining and triglyceride content by about 38%; in mice fed a high-fat diet, KPV by mouth reduced weight gain, fat tissue growth, liver enlargement and blood cholesterol ^[19]. In human liver cells (HepG2) loaded with oleic acid, KPV reduced fat accumulation without harming the cells ^[21]. These are early laboratory findings. They do not show that KPV causes weight loss in people, and the liver-cell study was about fat storage, not liver safety.

Researchers have also built modified versions of KPV. A dimer made of two KPV units joined by a cysteine bridge, (CKPV)2, was more potent than KPV at blocking the inflammatory signal TNF-α from human immune cells and reduced TNF-α in rats given bacterial endotoxin; in 2006 it was described as under clinical investigation as an antimicrobial ^[31]. We found no published trial results for it. In a 2024 mouse study, KPV assembled into nanoparticles with the drug rapamycin reduced calcium deposits in blood vessels ^[32]. These are separate molecules or combinations, and their results do not transfer to KPV sold on its own.

The KPV literature is small and almost entirely preclinical. Most gut findings come from a few laboratories, notably the Atlanta group that described PepT1 uptake ^{[4] [14] [33]} and Chinese groups working on hydrogels and nanoparticles ^{[20] [28] [34]}. Many of the newer studies were designed to test a delivery system, with KPV as the model drug, rather than to test KPV itself.

Several basic questions are unanswered. There are no published data on KPV’s half-life or absorption in people, no formal toxicology studies we could find, no dose-finding work, and no comparison of KPV with standard treatments for colitis or skin disease. A 2025 review of tripeptides in wound healing, which discussed KPV-loaded hydrogels, concluded that future research needs to improve the stability, bioavailability and delivery of these peptides before their clinical potential can be judged ^[35].

We found no published human trial of KPV. The FDA has stated that it had not identified any human exposure data on drug products containing KPV ^[7].

ClinicalTrials.gov had no registered trial of KPV when we searched in September 2026. Every claim about how KPV works in people, including testimonials from clinics that prescribe it, therefore rests on extrapolation from cells and rodents.

There is no human evidence on how long KPV takes to work. In animals, effects were measured over the course of an induced injury: the rabbit corneal study found full healing by 60 hours ^[17], and the mouse colitis studies followed animals through the days of a chemically induced flare and recovery ^{[4] [5]}. Those timelines depend on the injury model and do not predict what happens in a person.

Oral KPV is the best-studied route in animals, because the peptide transporter PepT1 in the gut can carry it into cells ^[4]. Mice have been given KPV in drinking water ^{[4] [5]} and in nanoparticles designed to release it in the colon ^[6], and mice fed a high-fat diet received it by mouth ^[19]. No study has measured how much of an oral dose reaches the blood in people, and KPV capsules and supplements sold online have not been tested in any published trial.

On the skin, KPV did not pass through human skin by simple diffusion in a 2017 laboratory study; permeation was below the detection limit. Pre-treating the skin with microneedles allowed it through, and adding a small electric current (iontophoresis) increased delivery further ^[22]. That suggests a plain KPV cream would deliver little through intact skin, although no product has been tested. Topical use in animals has involved eye drops ^[17], a gum gel ^[18] and skin application in allergic dermatitis ^[10].

We found no published study of KPV injections in people, and none of KPV nasal spray in any species. On stability, a 2015 analytical study found that under acid, alkali or oxidising stress KPV mainly broke down into a ring-shaped fragment of lysine and proline (a diketopiperazine) ^[23], which is one reason laboratory formulations use carriers to protect it.

Cell studies used nanomolar concentrations of KPV ^[4]. In mice, KPV has been given in drinking water ^[4] and in nanoparticle formulations by mouth ^[6]. These are animal and laboratory conditions, and no human dose has been established. The peptide calculator converts vial contents to concentrations but does not indicate an appropriate amount.

Other studies used 1, 5 or 10 mg/mL eye drops in rabbits ^[17], 50 µg/mL in skin cells ^[15] and 100 µg/mL in fat and liver cells ^{[19] [21]}. None of these translates into a human dose, and no KPV dosage chart, protocol or morning-versus-night timing has been tested in a published study.

Questions about KPV dosage in units are arithmetic. As an illustration only, a 10 mg vial dissolved in 2 mL of liquid gives 5 mg per mL; 0.1 mL of that solution holds 0.5 mg and is marked as 10 units on a U-100 insulin syringe. The volume of bacteriostatic water changes the concentration, not the amount in the vial, and the result is only right if the vial contains what its label says.

There are no human safety data for KPV. The FDA has said it cannot determine whether KPV would cause harm if given to people because no human exposure data have been identified ^[7]. The 2017 nanoparticle study reported that its KPV-loaded particles appeared non-toxic to intestinal cells ^[6], but cell and mouse findings do not establish safety in humans.

KPV peptide side effects described online, such as nausea, headache or effects on the liver, have not been recorded in any published study, so they can be neither confirmed nor ruled out. The liver-cell study sometimes cited for KPV and the liver examined fat storage in cultured cells and reported no toxicity to those cells; it did not assess liver safety in animals or people ^[21].

On KPV peptide cancer concerns: we found no study suggesting KPV causes cancer. In the one relevant mouse study, KPV prevented colitis-associated tumours in normal mice ^[14]. That is a single animal result, and it cannot be read as evidence that KPV prevents or is safe in cancer in humans. A 2026 review of peptide use in sport and bodybuilding, which named KPV among the peptides promoted for anti-inflammatory effects, warned that unregulated products are often mislabelled or contaminated and that long-term risks are poorly defined ^[24].

KPV and BPC-157 are unrelated peptides that are both marketed for gut health and inflammation. KPV is a three-amino-acid fragment of α-MSH studied as an anti-inflammatory in cells and in mouse colitis ^{[4] [5]}. BPC-157 is a 15-amino-acid peptide based on a gastric juice protein, studied mostly in rats for tendon, muscle and gut injury, with three small uncontrolled human reports and no controlled trials ^[25]. Its originating group describes rat work in colitis, fistulas and bowel surgery ^[26]. Our KPV vs BPC-157 comparison sets the two side by side.

Their proposed mechanisms differ. KPV is thought to dampen inflammatory signalling inside cells after entering through PepT1 ^[4], while BPC-157 research centres on blood-vessel growth and repair. Neither has a published human trial for any gut condition, and no study has compared them directly. The BPC-157 evidence is covered in full in its own guide.

BPC-157 and KPV are often sold together, and both appear in multi-peptide blends such as “KLOW”, which combines KPV with GHK-Cu, BPC-157 and TB-500, and “GLOW”, which leaves out KPV. We found no published study of BPC-157 and KPV together, of any blend containing KPV, or of whether these peptides stay stable when mixed in one vial. The reasoning sellers give, that one peptide calms inflammation while another supports repair, is a hypothesis and has not been tested. Information on the other peptides is in our guides to GHK-Cu and TB-500. What is and is not known about these blends is set out in Glow and Klow peptide blends.

KPV is not approved as a medicine anywhere we are aware of. In the US, the FDA previously placed KPV in category 2 of its interim compounding policy, the list of bulk substances that may present significant safety risks; the nomination was later withdrawn and the FDA now lists it among substances previously in category 2 ^[7].

On 23 July 2026, the FDA’s Pharmacy Compounding Advisory Committee met and considered KPV for wound healing and inflammatory conditions ^[9]. The FDA’s meeting page posted no votes or outcome, and as of September 2026 the FDA has not acted ^[9]. We have not confirmed KPV’s status on the WADA Prohibited List. For national rules, see our legal status overview and the US page.

In Canada, a Health Canada advisory in April 2026 named KPV among seized unauthorised peptide products and said that “research use only” labelling does not make such products legal ^[8]. The Canada legal status page has more detail.

KPV is sold as a freeze-dried powder. Peptides are generally stored cold, dry and away from light, and reconstituted solutions are refrigerated and used within a limited period. See how to store peptides.

Formulation studies give some hints about KPV’s stability. Under acid, alkali or oxidising stress it breaks down mainly into a lysine-proline diketopiperazine ^[23]. Two hydrogel studies reported that free KPV lost activity faster than KPV held in their gels when warmed, at 37 °C in one and 50 °C in the other ^{[34] [20]}. None of these studies tested storage conditions for the powders sold online, so they do not establish a shelf life.

Compare prices, read how to read a COA, and look for third-party tested suppliers.

We track listings for KPV peptide UK prices and Australian prices, but a listing does not mean a product is legal to buy where you live. Because KPV is a very small molecule, a mass spectrometry result matching its mass of about 342 g/mol is a straightforward identity check. Our guide to spotting a fake peptide supplier lists other warning signs.